Oslo, November 12[th], 2024 – Observe Medical ("the Company" or "Observe Medical") has today signed the DOC (Declaration of Conformity). This marks the final step for the establishment of a high-volume manufacturing platform for the UnoMeter™ product portfolio, consisting of UnoMeter™ 500 and UnoMeter™ Safeti™ Plus. The DOC is the final regulatory documentation that needs to be…
Oslo, August 22, 2024 – Observe Medical ("the Company" or "Observe Medical") has received its first order of UnoMeter 500 products from a distributor in South America. This initial order represents a significant step towards expanding our footprint in a region that holds historical importance for the UnoMeter product line. This marks a significant milestone as…
Oslo, August 19, 2024 -Observe Medical ("the Company" or "Observe Medical") will release its results for the first half year 2024 on Monday, 26 Augsut 2024. The presentation will be published on NewsWeb and theCompany's website at 07:00 CET on the same day. The Company will host a presentation and Q&Asession at 10:00 CET on…
Oslo, 25 June 2024 Reference is made to the announcement made by Observe Medical ASA (the "Company" or "Observe Medical", and, together with its subsidiaries, the "Group", OSE ticker "OBSRV") yesterday, on 24 June 2024, regarding the successfully placed private placement of new shares in the Company to raise gross proceeds of NOK 22 million…
Oslo, 4 June 2024 – Observe Medical ASA ("the Company" or "Observe Medical") announces that it has entered into a Letter of Intent (LOI) with Sulacare AS ("Sulacare") to collaborate on the commercial launch of Sulacare's innovative and proprietary female catheterization product. This partnership goes beyond leveraging Observe Medical’s established platform to commercialize and distribute…
Oslo, 3 June 2024 – Observe Medical ASA ("the Company" or "Observe Medical") continues to see positive momentum in the re-adoption of its UnoMeter™ brand of medical devices into NHS and across private hospitals in the United Kingdom and Ireland. Building on previous announcements, Observe Medical confirms that since the start of 2024, UnoMeter™…
Oslo, 31 May 2024 – Observe Medical ASA ("the Company" or "Observe Medical") announces that its subsidiary, Biim AS ("Biim"), has extended its agreement with Fresenius Medical Care ("Fresenius") for the supply of wireless pocketable ultrasound devices. The initial agreement with Fresenius was entered into in October 2021, with a one-year extension exercised in October…
Oslo, 27 May 2024 – Observe Medical ASA ("the Company" or "Observe Medical") is pleased to announce the early launch of the UnoMeter[TM] Safeti Plus, a market-leading Hourly Diuresis Monitoring System with a proven track record of safety and effectiveness. This early launch is a direct result of the strong collaboration between Observe Medical's product…
Oslo, April 18, 2024 – Observe Medical ASA (the "Company" or "Observe Medical") announces transfer of its Nordic distribution operations to Vingmed, following a strategic review. The Company assessed the relevance of the business, originally established as a platform for testing and launching its branded products. Given the expansion of our global distribution capabilities, which now…
Oslo, March 11, 2024 – Observe Medical ASA (the "Company" or "Observe Medical") announces that the Group, via its UK distributor C&P Medical, has been awarded onto the Scottish NHS Urology Framework with Unometer[TM ]500. This is a 3 year contract until end of March 2027, effective from April 2024. NHS Scotland consists of 14…
Oslo, March 6, 2024 -Observe Medical ("the Company" or "Observe Medical") will release its results for the second half and full year 2023 on Wednesday, 13 March 2024. The presentation will be published on NewsWeb and theCompany's website at 07:00 CET on the same day. The Company will host a presentation and Q&Asession at 08:30…
Oslo, February 28, 2024 -Observe Medical ("the Company" or "Observe Medical") has received the first order for its UnoMeter products from Siramo GmbH, following the strategic Letter of Intent (LOI) announced in December 2023. This order marks the expansion into the German market, a key territory for the distribution of the UnoMeter product range. The…
Oslo, February 13, 2024 – Observe Medical ("the Company" or "Observe Medical") has received first orders for delivery of UnoMeter™ 500 products from our distributor in Ireland, Armstrong Medical. We are set to dispatch 2,800 units of the UnoMeter™ 500 this week, with an additional 2,500 units scheduled for shipment by the end of February. The…
Oslo, January 18, 2024 – Observe Medical ("the Company" or "Observe Medical") announces the expansion of its UnoMeter portfolio into the Asian market, with UnoMeter 500 orders received from Thailand and Vietnam. This expansion not only diversifies our market presence but also reinforces Observe Medical’s commitment to global growth and establishing a strong foothold in regions…
Oslo, 18 January 2024: Reference is made to the stock exchange announcement published by Observe Medical ASA (the "Company" or "Observe Medical") on 12 December 2023 regarding the final results of the rights issue of minimum 69,230,770 new shares and maximum 211,538,461 new shares in the Company at a subscription price of NOK 0.26 per…
Oslo, January 4, 2024 – Observe Medical ("the Company" or "Observe Medical") has received first order from our distributor in Portugal, Aviquímica, for delivery of UnoMeter 500 products. The UnoMeter portfolio is experiencing rapid expansion, having recently secured orders from Portugal, bringing the total count to 18 countries. The favorable clinical evaluations contribute positively to the…
Oslo, December 12, 2023 – Observe Medical ("the Company" or "Observe Medical") is thrilled to share that the production capacity of our flagship product, UnoMeter 500, has now reached a level on par with the historical benchmarks set by Convatec. In a remarkably short span of time, we have achieved a production capacity equivalent to Convatec's…
Oslo, December 8, 2023 – Observe Medical (the “Company" or "Observe Medical") is excited to announce a significant milestone in our global expansion strategy with the signing of a Letter of Intent (LOI) for distribution of the UnoMeter portfolio in the German market. The agreement marks our entry into the German market and has been formalized…
Oslo, December 6, 2023 – Observe Medical (the “Company" or "Observe Medical") has received first order for delivery of UnoMeter 500 and Abdo Pressure products from our distributor in Croatia, Stoma Medical. The UnoMeter portfolio is experiencing rapid expansion, having recently secured orders from Croatia, bringing the total count to 17 countries. The favorable clinical…
Oslo, November 29, 2023 – Observe Medical (the "Company" or "Observe Medical") has received first order for delivery of UnoMeter Abdo Pressure products from our distributor in Slovakia, Unomed. The UnoMeter portfolio is rapidly extending its reach and with the addition of Slovakia, we have now secured orders from a total of 16 countries. With…
Oslo, 29 November 2023 – Observe Medical ASA (OSE: OBSRV) (the “Company" or "Observe Medical") will host a Company presentation Monday 4 December 2023, at 13:00 CET. The presentation will take place virtually on Microsoft Teams Live Event, and is hosted by SpareBank 1 Markets. Please use the following link to join www.bit.ly/OBSRV23 (https://eur03.safelinks.protection.outlook.com/?url=httpwww.bit.lyOBSRV23&data=0501perarne.nygardobservemedical.comffccd96ce09a4a65ebb808dbefeb08dc139dbc03ecf246efb467a338c990a8d600638367564980273081UnknownTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn03000&sdata=9CZ7I1MkfbxrBhwzeMxEcPdP1AGrmZQwHXmugcC33U&reserved=0). The presentation…
Oslo, November 28, 2023 – Observe Medical ("the Company" or "Observe Medical") announces a new order and distribution agreement with ReplantMed, our Hungarian distributor. The UnoMeter portfolio is continuously expanding footprint with total orders from 15 countries, demonstrating its widespread market and global demand. Positive clinical evaluations further strengthen the quality and performance of the UnoMeter…
Oslo, November 13, 2023 – Observe Medical ("the Company" or "Observe Medical") is pleased to announce the signing of a Letter of Intent (LOI) for a forthcoming exclusive Nordic distribution agreement for the UnoMeter portfolio with leading Nordic distributor Vingmed. This LOI represents a significant step towards the continuation of a strong presence in the Nordic…
Oslo, November 10, 2023 – Observe Medical ("the Company" or "Observe Medical") has received follow-up orders from several distributors including the Spanish distributor, BM2 Health, for delivery of UnoMeter Abdo Pressure products, with most recent follow-up orders having a value of approx. NOK 1,3 million. The total value of orders for the UnoMeter product range has…
Oslo, October 26, 2023 – Observe Medical ("the Company" or "Observe Medical") today announces the shipment of the first UnoMeter[TM] 500 products to distributors in Poland and Spain. Containers carrying over 96,000 UnoMeterTM 500 products are now loaded at our OEM factory and set to ship on October 30th, which build upon the previous stock announcement…
Oslo, October 17, 2023 – Observe Medical (OSE: OBSRV) Observe Medical ("the Company" or "Observe Medical") today announces that it has delivered 20 Biim ultrasound probes to Fresenius Medical Care in the US. As part of the partnership agreement with Fresenius Medical Care, Observe Medical has delivered 20 Biim ultrasound probes to Fresenius Medical Care,…
Oslo, 19 June 2023 – Observe Medical ASA ("the Company" or "Observe Medical") has signed a first contract with a UK customer for delivery of Unometer[TM] products[*]. This marks the first entry into the UK market, which historically has accounted for a large share of Unometer[TM] sales. In parallel, Observe Medical has attained CE certification…
Link to the recording of the live event: https://attendee.gotowebinar.com/recording/1358614173515479296 For further information, please contact: Rune Nystad, CEO Observe Medical Mobile: +47 916 24 683 E-mail: rune.nystad@observemedical.com Per Arne Nygård, CFO of Observe Medical Mobile: +47 411 04 345 E-mail: perarne.nygard@observemedical.com About Observe Medical Observe Medical is a Nordic medtech company that develops, markets and sells innovative medtech…
Oslo, 5 June 2023 – Observe Medical ASA (OSE: OBSRV) (“the Company” or “Observe Medical”) will host a Company presentation Tuesday, 6 June 2023, at 14:00 CEST. The presentation will take place virtually on Microsoft Teams Live Event, and is hosted by SpareBank 1 Markets. Please register to corporateaccess@sb1markets.no to receive a link to join.…
Oslo, 20 April 2023 – Observe Medical ASA ("the Company" or "Observe Medical") today announces it has informed Ferrari L., an Italian manufacturer of medical equipment, that the Company has decided to discontinue the process of acquiring Ferrari L. The contemplated acquisition was originally announced in a press release on 14 December 2022. This decision…
Oslo, 6 March 2023 – Observe Medical ASA (“the Company” or “Observe Medical”) has prepared an updated company presentation which can be found attached. The presentation is also available on www.observemedical.com For further information, please contact: Rune Nystad, CEO Observe Medical Mobile: +47 916 24 683 E-mail: rune.nystad@observemedical.com Per Arne Nygård, CFO of Observe Medical Mobile:…
Oslo, 3 March 2023 – Observe Medical ASA (“the Company” or “Observe Medical”) today provides an update on the initial letters of intent (LOIs) that have been sent to distributors of the Unometer portfolio. As previously announced, Observe Medical is in the process of confirming orders with distributors of Unometer Safeti Plus, AbdoPressure and Sippi.…
Oslo, March 2, 2023 – Observe Medical ASA (OSE: OBSRV) ("Observe Medical" or the "Company"), a Nordic-based medtech company focused on developing and commercializing proprietary and innovative medtech products to the global market through organic growth and targeted M&A, today publishes a shareholder letter. The letter to our shareholders is enclosed to this release. For further information, please…
Oslo, 10 February 2023 – Observe Medical ASA (“the Company” or “Observe Medical”) will release its fourth quarter 2022 results on Friday, 17 February 2023. The presentation will be made available on NewsWeb and the Company's website at 07:00 CET on the same day. Rune Nystad, CEO, and Per Arne Nygård, CFO, will host a presentation…
Oslo, January 10, 2023 – Observe Medical ASA (OSE: OBSRV) ("Observe Medical" or the "Company"), a Nordic-based medtech company focused on developing and commercializing proprietary and innovative medtech products to the global market through organic growth and targeted M&A, today publishes a shareholder letter. The letter to our shareholders is enclosed to this release. For further information, please…
Oslo, 10 January 2023 – Observe Medical ASA ("the Company" or "Observe Medical") announces it has appointed Jørgen Mann as the Company’s Chief Commercial Officer. With nearly 20 years of experience in sales and senior management roles from global medtech companies in Europe, he brings highly relevant experience to Observe Medical, as the company strengthens…
Oslo, December 15, 2022 – Observe Medical ASA ("Observe Medical" or "the Company") today announce that Rune Nystad, CEO of Observe Medical, will present at the 13th annual DNB Nordic Healthcare Conference in Oslo, Norway, today on Thursday, December 15, 2022, at 15.35 CET. The presentation is attached to this announcement. For further information, please…
Oslo, December 14, 2022 – Observe Medical ASA ("Observe Medical" or "the Company") has entered into an exclusivity agreement to negotiate an acquisition of Ferrari L. di Ferrari Pietro S.r.l. and Ferrari Luigina S.r.l. (together "Ferrari L."), which owns and operates a production facility for medical and surgical equipment located in Verona, Italy. Ferrari L.…
Oslo, October 26, 2022 – Observe Medical ASA (OSE: OBSRV) ("Observe Medical"or the "Company"), will release its third quarter 2022 results on Thursday, 3 November 2022. The presentation will be made available on NewsWeb and the Company’s website at 07:00 CET on the same day. Rune Nystad, CEO, and Per Arne Nygård, CFO, will host…
Oslo, October 25, 2022 – Observe Medical ASA (OSE: OBSRV) ("Observe Medical" or the "Company"), a Nordic-based medtech company focused on developing and commercializing proprietary and innovative medtech products to the global market through organic growth and targeted M&A, today publishes a shareholder letter. The letter to our shareholders is enclosed to this release. For…
Oslo, 9 September 2022 – Observe Medical ASA (“the Company” or “Observe Medical”), is pleased to announce the appointment of Carsten Trygve Bøgh as Chief Technology Officer (CTO), effective 2 October 2022. Mr. Bøgh has a long-standing medtech career, having led several innovative product launches, delivered impactful results, and reached value-inflection milestones for companies. “We…
Oslo, September 5, 2022 – Observe Medical ASA (OSE: OBSRV) ("Observe Medical" or the "Company"), a Nordic-based medtech company focused on developing and commercializing proprietary and innovative medtech products to the global market through organic growth and targeted M&A, today publishes a shareholder letter (in Norwegian). The letter to our shareholders is enclosed to this…
Oslo, 2 June 2022 – Observe Medical ASA (OSE: OBSRV) ("Observe Medical"or the "Company"), will release its first quarter results for 2022 on Friday, 3 June 2022. The presentation will be available on Newsweb and the Company’s website at 07:00 CET. Following the release, CEO, Rune Nystad and CFO, Per Arne Nygård will host a…
Oslo, 28 April 2022 – Observe Medical ASA ("the Company" or "Observe Medical") today announces that it has delivered an additional 58 Biim ultrasound probes to Fresenius Kidney Care in the US, completing the delivery of a total of 260 ultrasound probes in the first phase of the delivery to Fresenius Kidney Care as planned.…
Oslo, April 1, 2022 – Observe Medical ASA ("the Company" or "Observe Medical") today announces that the Sippi® Disposable Unit has received Medical Device Regulation Certification, ensuring continued market access for the unit in Europe after 2024. Rune Nystad, CEO of Observe Medical, commented: "The MDR Certification confirms that the Sippi® Disposable Unit is compliant with…
Oslo, March 28, 2022 – Observe Medical ASA (OSE: OBSRV) ("Observe Medical" or the "Company"), will be announcing its fourth quarter 2021 results on Tuesday 29 March 2022. Members of the Management team will host a presentation at Haakon VIIs gate 2 in Oslo and the event will start at 08.30 CET. The live webcast will…
Oslo, October 22, 2021 – Observe Medical ASA (OSE: OBSRV) continues its rollout of Sippi®, and reports clinical implementation at several sites in Europe – including use outside intensive care units, and clinical evaluations driving the health economic value of Sippi® “We are excited to see Sippi® implementation gaining momentum as society and hospitals now…
Oslo, September 27th, 2021 – Observe Medical ASA (OSE: OBSRV) continues its rollout of Sippi®, and today announces that a major regional hospital in Italy has decided to implement Sippi® in the intensive care unit (ICU), with wireless connection to the hospital’s patient data management system. “The decision by a major Italian hospital to implement…
Oslo June 30, 2021 – Observe Medical ASA (OSE: OBSRV), today announces that it has entered into a distribution agreement and partnership with Skamex (Poland) for the launch of Sippi® in the Polish and the Romanian market. “We are pleased to announce that we are taking additional steps in the roll-out of Sippi® through our…
Oslo May 07, 2021 – Observe Medical ASA (OSE: OBSRV), announces that Nya Karolinska Sjukhuset, Sweden, prepares new studies to broaden the clinical scope of use for Sippi® automated, digital urine measurement system, building further on the results from the recent dissertation by Dr Martin Slettengren. Following the recent dissertation by Dr. Martin Slettengren, ”Evaluation…